Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.

The Prostate - 1 May 2002

Yashi Masahiro, Muraishi Osamu, Kobayashi Yutaka, Tokue Akihiko, Nanjo Hiroshi

Abstract excerpt

BACKGROUND: Increases in neuroendocrine phenotype and secretory products are closely correlated with tumor progression and androgen independence in prostate cancer. In this study, we explored this correlation using serum progastrin-releasing peptide (ProGRP), a carboxy-terminal region common to three subtypes of precursors for gastrin-releasing peptide (GRP), which is released from the neuroendocrine phenotype to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgens
Share to Enzyme-Linked Immunosorbent Assay

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrins

Share to Longitudinal Studies

Share to Neoplasm Metastasis

Share to Peptide Fragments

Share to Prostate-Specific Antigen

Share to Protein Precursors

Source

Identifiers

PMID: 11948963
DOI: 10.1002/pros.10063

Genes

GRP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.PMID 11948963Read ↗

The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.Semantic proximity Read ↗

Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.Semantic proximity Read ↗

G Proteins in Cancer: The Prostate Cancer ParadigmSemantic proximity Read ↗

Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.Semantic proximity Read ↗

Neuroendocrine differentiation in prostatic carcinoma.Semantic proximity Read ↗

Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.Semantic proximity Read ↗

Protein kinase A-mediated phosphorylation of RhoA on serine 188 triggers the rapid induction of a neuroendocrine-like phenotype in prostate cancer epithelial cells.Semantic proximity Read ↗

Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells.Semantic proximity Read ↗

Neuroendocrine cells in tumour growth of the prostate.Semantic proximity Read ↗

Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.Semantic proximity Read ↗

Adrenomedullin (AM) and AM receptor type 2 expression is up-regulated in prostate carcinomas (PC), and AM stimulates in vitro growth of a PC-derived cell line by enhancing proliferation and decreasing apoptosis rates.Semantic proximity Read ↗

Interferon-gamma induces neuroendocrine-like differentiation of human prostate basal-epithelial cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.